Why It Matters
Hope is here. The cost is the barrier.
In a Phase III trial, people with metastatic pancreatic cancer who took this treatment lived about twice as long as those on standard chemotherapy. About 7,500 people in Canada are diagnosed with pancreatic cancer each year, and most pancreatic cancers carry the RAS gene change this treatment targets.
Median overall survival · Phase III RASolute 302
Accessible in Canada, but not affordable
Canadian oncologists can request this treatment through Health Canada's Special Access Program. It costs ~$55,000 a month, and few families can pay that.
Not covered by public drug plans
The US FDA approved this treatment on August 26, 2026. No Canadian approval decision has been announced, so public drug plans don't cover it.
Canadian trials don't cover most people
The RASolute 303 trial is recruiting at Princess Margaret in Toronto and McGill in Montreal, but only for newly diagnosed people who haven't been treated for metastatic disease.
The standard Health Canada process can take years
Each step follows the one before it. Together, they usually delay coverage until 2027–2028.
Our ask
Cost should not decide who gets this treatment.
We're asking for a compassionate or cost-shared supply program from the manufacturer, and provincial exceptional-access funding, so every Canadian patient who needs this treatment can receive it.
Affordable access for every patient in Canada who needs this treatment.
The SAP already works for drugs like this
Health Canada routinely grants SAP access to cancer drugs awaiting Canadian approval.
It has been done before
Before Trikafta, a cystic fibrosis drug, was approved in Canada, about 165 Canadians received it free through compassionate supply.
The pieces are already here
Health Canada has authorized trials of this treatment at Princess Margaret and McGill, so the drug, the doctors and the supply routes are already in Canada.
Thank you
Your voice is counted.
The next most helpful thing is to share this page with one person who would want to add theirs.
Preview only: nothing was saved. On the live site this form sends your details to the campaign.
Thank you. Your answers were added to your voice.
More ways to help
Help the word travel.
Share this page
Send it to anyone in Canada affected by pancreatic cancer.
pancreaticcantwait.ca
Make an introduction
Do you know an oncologist, nurse navigator, patient group, journalist, or someone at Revolution Medicines or in health policy? Email us at support@pancreaticcantwait.ca.
Questions
Frequently asked questions
What is this treatment?
Rasonque™ (daraxonrasib) is a treatment for metastatic pancreatic cancer, taken as pills by mouth at home. It targets RAS, a gene change found in most pancreatic cancers.
The US FDA approved it on August 26, 2026. In a Phase III trial, people who took it lived a median of 13.2 months, compared with 6.7 months on standard chemotherapy.
Can people in Canada get Rasonque (daraxonrasib) today?
Yes, but only through Health Canada's Special Access Program (SAP), and at ~$55,000 a month. Health Canada hasn't approved it for sale, so public drug plans don't cover it.
A clinical trial (RASolute 303) is enrolling at Princess Margaret in Toronto and McGill in Montreal, but only for newly diagnosed people who haven't been treated for metastatic disease.
What is the Special Access Program (SAP)?
The SAP is a Health Canada program that lets doctors request drugs that aren't yet sold in Canada. It's for people with serious or life-threatening conditions when usual treatments have failed, aren't suitable or aren't available.
Many cancer drugs reach people in Canada this way while Canadian approval is still pending.
Can my oncologist apply for me?
Only a doctor can make an SAP request. Patients can't apply directly.
Even when Health Canada approves a request, the drug's maker decides whether to supply it and on what terms, including the price. That's why we're working toward a path that doesn't depend on what a family can pay.
Whether this treatment is right for you is a conversation to have with your oncologist.
How much does Rasonque (daraxonrasib) cost in Canada?
Rasonque (daraxonrasib) currently costs about $55,000+ CAD per month and is not covered by Canadian public or private drug plans.
We're pursuing two main funding routes: assistance from Revolution Medicines to reduce or cover the cost, and case-by-case public funding through provincial drug programs. Neither is guaranteed.
Is this a clinical trial?
No. The SAP is a way to get a drug for one person's care, not a research study. Doctors do report back to Health Canada on how the patient is doing.
What happens to my information when I add my voice?
We use it only for this campaign. Totals, such as how many people in each province support the ask, may be shared with decision-makers and the press.
Your name appears only the way you choose. Your story is quoted only if you say yes. We never sell or share your contact details. To stop hearing from us, email support@pancreaticcantwait.ca.
Who is behind this campaign?
Pancreatic Cancer Can't Wait is a patient-led campaign started by Salman Syed in Ontario, and it's now carried forward by a growing group of patients, families and advocates across Canada. We're independent of Revolution Medicines and Health Canada.
For the first time, there's a pill that can double our time. I'm fighting to make sure Canadians get that time too.
About
A patient-led campaign.
Pancreatic Cancer Can't Wait was started by Salman Syed, a husband and father of two in Ontario who is conquering metastatic pancreatic cancer. It's now carried forward by a growing group of patients, families and advocates across Canada.
We are independent of Revolution Medicines and Health Canada. We welcome everyone who shares the goal, of every faith and none.
This site is not medical advice. Whether this treatment is right for someone is a decision for that person and their oncologist.